Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1767P - Co-clinical PDX study of trastuzumab deruxtecan in HER2-positive uterine carcinosarcoma (STATICE trial, NCCH1615)

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy;  Translational Research;  Cancer in Special Situations/ Populations;  Rare Cancers

Tumour Site

Ovarian Cancer;  Sarcoma

Presenters

Shigehiro Yagishita

Citation

Annals of Oncology (2021) 32 (suppl_5): S1211-S1226. 10.1016/annonc/annonc716

Authors

S. Yagishita1, T. Nishikawa2, H. Yoshida3, D. Shintani4, S. Sato4, M. Miwa4, M. Suzuki1, M. Yasuda5, K. Yonemori2, K. Hasegawa6, A. Hamada1

Author affiliations

  • 1 Molecular Pharmacology, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 2 Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Diagnostic Pathology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Department Of Gynecologic Oncology, Saitama Medical University International Medical Center, 3501298 - Saitama/JP
  • 5 Department Of Pathology, Saitama Medical University International Medical Center, 3501298 - Saitama/JP
  • 6 Department Of Gynecologic Oncology, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1767P

Background

Uterine carcinosarcoma (UCS) is a rare and highly aggressive disease, which has been categorized as a subtype of high-grade endometrial cancer but not uterine sarcoma. A high clinical efficacy of a novel anti-HER2 antibody drug conjugate, trastuzumab deruxtecan (T-DXd), in HER2-positive UCS will be reported at ESMO2021 (STATICE TRIAL). Herein, we report a co-clinical study of T-DXd using patient-derived xenograft (PDX) models of patients that participated in the STATICE trial.

Methods

Tumor specimens were resected at primary surgery or biopsied at recurrence from UCS patients at Saitama Medical University International Medical Center. Those specimens were transplanted into immunodeficient mice at the National Cancer Center Research Institute. A total of seven UCS-PDXs were established, and HER2, ER, and p53 expression of PDX tumor and original tumor was assessed using Ventana I-VIEW Pathway HER2 kit (4B5, Roche, Arizona, USA), Ventana I-VIEW confirmed ER kit (SP1, Roche), and anti-p53 antibody (DO-7, Agilent, California, USA), respectively. Drug efficacy tests were conducted using six of seven PDXs in three groups: control, T-DXd 3 mg/kg, and 10 mg/kg. All drugs were administered through the tail vein on day 0.

Results

Of the six UCS-PDXs tested, two PDXs were derived from patients who were treated with T-DXd in the STATICE TRIAL. The histopathological characters of the six PDXs were well-conserved compared with each original tumor. HER2 expression was 1+ in all PDXs, and the expression of ER and p53 maintained the characteristics of the original tumors. Significant tumor shrinkage of T-DXd at both 3 mg/kg and 10 mg/kg dosing was demonstrated in four out of the six PDXs (67%), comparable to the response rate (70%) of HER2 1+ patients in STATICE TRIAL. Two patients had partial response as the best response, and the clinical effect was well replicated with significant tumor shrinkage in each UCS-PDX.

Conclusions

The UCS PDX models appear predictive of clinical efficacy and an effective preclinical evaluation platform as the results are consistent with response rates observed in the STATICE trial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

National Cancer Center, Tokyo, Japan Saitama Medical University International Medical Center, Saitama, Japan.

Funding

Japan Agency for Medical Research and Development National Cancer Center Research and Development Fund Daiichi Sankyo Co. Ltd.

Disclosure

T. Nishikawa: Financial Interests, Personal, Speaker’s Bureau: Eisai; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Takeda Pharmaceutical company; Financial Interests, Personal, Advisory Board: Eisai. K. Yonemori: Financial Interests, Personal, Speaker’s Bureau: Eisai; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Takeda Pharmaceutical Company; Financial Interests, Personal, Advisory Board: Chugai Pharmaceutical Company; Financial Interests, Personal, Advisory Board: Ono Pharmaceutical Company; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Daiichi Sankyo Company. K. Hasegawa: Financial Interests, Institutional, Funding: Daiichi Sankyo Co. Ltd.; Financial Interests, Personal, Speaker’s Bureau: Daiichi Sankyo Co. Ltd. A. Hamada: Financial Interests, Institutional, Funding: Daiichi Sankyo Co. Ltd.. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.